Skip to content
GlaxoSmithKline Pharmaceuticals logo

GlaxoSmithKline Pharmaceuticals

GLAXO NSE
₹2,727.60 +14.20 (+0.52%)
Market Cap
₹46,207 Cr
P/E
40.30
View as Markdown
MCP
Close 20 Nov 2026 ₹2,727.60 1Y +250.60 +10.1%
Start ₹2,477.00

Key Fundamentals

MidcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
61.40%
Debt to Equity
0.02
EPS (TTM)
₹67.68
Book Value
₹111.04
Market Cap
₹46,207 Cr
P/E (TTM)
40.30
P/B
24.56
ROE
45.60%
Dividend Yield
2.10%
EBITDA
₹1,455 Cr
52W High
₹3,120.70
52W Low
₹2,088.10
Day Range
₹2,680.00 – ₹2,748.00
Volume
84,480

Peer Comparison

Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals

GlaxoSmithKline Pharmaceuticals peer comparison
1,884.9041.254,52,2515.070.85%16.00%20.50%61,63110,987
11,180.5088.262,96,80716.490.27%16.50%22.00%12,1913,363
4,689.5077.801,78,3749.710.82%27.40%15.20%17,4002,099
2,294.6092.521,23,98020.450.04%18.30%17.80%7,8231,332
1,200.0028.631,19,7004.300.08%21.20%21.10%30,3784,303
1,390.2041.441,16,0372.990.57%11.20%13.00%33,0972,760
1,415.0039.451,14,3123.230.92%11.60%15.50%28,1392,855
2,727.6040.3046,20724.562.16%45.60%61.40%4,1591,147
Median 8 companies2,089.7541.351,21,8407.390.70%17.40%19.15%22,7702,808

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

56 Good

Data confidence 100/100

Category scores

Quality
77
Strong
Returns, margins, earnings quality 22% weight
Valuation
58
Good
Cheap vs sector & own history 24% weight
Growth
30
Poor
Sales & profit trajectory 9% weight
Financial Health
84
Strong
Solvency, leverage, coverage 9% weight
Momentum
34
Poor
Trend strength, vol-adjusted 12% weight
Ownership
54
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Company has a good return on equity (ROE) track record: 3 Years ROE 43.5%
  • Company has been maintaining a healthy dividend payout of 94.6%

Weaknesses

2
  • Stock is trading at 24.6 times its book value
  • The company has delivered a poor sales growth of 5.49% over past five years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish2512
OscillatorsNeutral252
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
59.61
Neutral
MACD (12,26,9)
25.58
Bullish
SMA (50)
2,657.15
Bullish
SMA (200)
2,533.22
Bullish

As of

Analyst Rating

Based on 4 analysts
BUY75%

3 of 4 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
3
75%
HOLD
1
25%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+3.02%
5Y+5.49%
3Y+5.53%
1Y+1.95%
TTM+12.14%

Net profit

Net profit growth by window
10Y+10.67%
5Y+23.68%
3Y+19.24%
1Y+11.64%
TTM+20.10%

Operating cash flow

Operating cash flow growth by window
10Y+20.58%
5Y+9.33%
3Y+23.11%
1Y−30.00%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+17.41 pp
5Y+13.81 pp
3Y+9.53 pp
1Y+2.80 pp
TTM+1.46 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹2,908 Cr
Mar 2018₹2,871 Cr
Mar 2019₹3,128 Cr
Mar 2020₹3,224 Cr
Mar 2021₹2,926 Cr
Mar 2022₹3,278 Cr
Mar 2023₹3,252 Cr
Mar 2024₹3,454 Cr
Mar 2025₹3,749 Cr
Mar 2026₹3,822 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹337 Cr
Mar 2018₹351 Cr
Mar 2019₹445 Cr
Mar 2020₹93.00 Cr
Mar 2021₹358 Cr
Mar 2022₹1,695 Cr
Mar 2023₹611 Cr
Mar 2024₹590 Cr
Mar 2025₹928 Cr
Mar 2026₹1,036 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹428 Cr −9.9% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 16 Nov 2026
AI opinion · based on fundamentals
Risk medium

As of 2026-11-16, GlaxoSmithKline Pharmaceuticals Ltd trades at ₹2,651.7 with a market cap of ₹44,921.4 crore, commanding a TTM P/E of 39.18x and P/B of 23.88x. The company operates as a virtually debt-free entity with a ROE of 45.69% and ROCE of 55.36%, though its five-year revenue CAGR of 5% reflects modest topline expansion relative to its premium valuation.

Bull Case 8
  • Exceptional return on equity of 45.69% as of 2026-11-16, with a three-year average ROE of 43.5%, indicating highly efficient capital deployment relative to pharma peers.
  • Virtually debt-free balance sheet with a debt-to-equity ratio of just 0.01, providing significant financial resilience and flexibility for future investments.
  • ROCE of 55.36% signals that the company generates substantial returns on total capital employed, reflecting strong pricing power and operational efficiency.
  • TTM profit growth of 19% and a three-year compounded profit growth of 18% demonstrate accelerating earnings momentum, outpacing the 10-year profit CAGR of 10%.
  • Healthy dividend yield of 2.13% supported by a payout ratio of 94.6%, offering consistent cash returns to shareholders.
  • TTM sales growth has accelerated to 12%, a meaningful improvement over the five-year compounded sales growth of 5%, suggesting improving demand or product mix.
  • The stock trades roughly 15% below its 52-week high of ₹3,120.7, having recovered significantly from its 52-week low of ₹2,088.1, reflecting a price correction from peak levels.
  • Ten-year ROE averaging 33% underscores a long track record of consistently high profitability through multiple market cycles.
Bear Case 7
  • Five-year compounded sales growth of just 5% indicates structurally slow topline expansion for a company commanding a P/E of 39.18x.
  • TTM P/E of 39.18x is a significant premium to broader market and sector averages, embedding high growth expectations into the current price.
  • Ten-year compounded revenue growth of only 3% raises questions about the company's ability to sustain meaningful topline acceleration over extended periods.
  • A dividend payout ratio of 94.6%, while rewarding shareholders, leaves very limited retained earnings for organic reinvestment, R&D, or new product launches.
  • The stock's 10-year price CAGR of 7% has lagged its profit growth CAGR of 10% over the same period, suggesting the market has periodically de-rated the stock.
  • Five-year stock price CAGR of 10% and one-year return of 6% indicate modest capital appreciation relative to the high valuation multiples the stock commands.
  • Despite TTM sales growth accelerating to 12%, the gap between the 10-year sales CAGR of 3% and 10-year profit CAGR of 10% suggests earnings growth has leaned on margin expansion, which may have limited further room.

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

23h ago

TL;DR: GSK Pharma delivered a strong Q2FY27 with 31% profit growth and 21% revenue expansion, signaling healthy operational momentum. No material headwinds emerged in the recent news cycle. The ₹630 crore RPT with GSK Biological is routine parent-subsidiary business. If the double-digit top-line growth sustains, the earnings trajectory remains firmly positive heading into H2FY27.

Positives 1
  • Q2FY27 profit jumps 31% YoY Nov 3

    Standalone net profit rose 31% YoY to ₹334.6 crore in Q2FY27. Revenue from operations grew 21% YoY to ₹1,179.9 crore.

Neutral 2
  • ₹630 crore RPT approval sought Nov 17

    GSK Pharma seeks shareholder approval for related party transactions up to ₹630 crore with GSK Biological S.A. for FY27.

  • Analyst meet held Nov 4 Oct 28

    GSK Pharma hosted a digital analyst and institutional investor meeting on November 4, 2026, with the video recording uploaded on November 5.

Quarterly Results

₹ Cr
GLAXO quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
957
805
930
815
1,011
949
974
805
980
1,041
995
938
1,184
Expenses
668
587
673
584
689
658
641
554
644
670
644
643
782
Operating Profit
289
218
257
231
322
292
333
251
336
371
351
296
402
OPM %
30%
27%
28%
28%
32%
31%
34%
31%
34%
36%
35%
31%
34%
Other Income
28
28.11
29.83
36
34.54
35
41
44
33.57
50
36
44
72.78
Interest
0
0
1
0
0
0
1
0
1
1
1
1
0.49
Depreciation
18
17
18
16
17
19
15
16
17
20
13
16
15.02
Exceptional Items
—
−163
2.4
—
4.69
—
—
—
2.64
—
—
—
—
PBT
299
65
271
249
344
308
359
279
354
400
373
322
459
Tax %
27%
30%
28%
27%
27%
25%
27%
27%
27%
26%
26%
26%
27%
Net Profit
218
46
194
182
252
230
263
205
257
296
278
237
336
EPS (₹)
12.84
2.70
11.48
10.76
14.91
13.57
15.52
12.10
15.20
17.45
16.40
14.00
19.83
YoY Sales growth
4
0
18
7
6
18
5
−1
−3
10
2
17
21

Profit & Loss

₹ Cr
GLAXO profit and loss, annual, ₹ crore
Particulars Mar 2015 15mMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
3,305
2,838
2,908
2,871
3,128
3,224
2,926
3,278
3,252
3,454
3,749
3,822
4,159
Expenses
2,672
2,360
2,489
2,363
2,527
2,567
2,327
2,516
2,447
2,545
2,570
2,512
2,739
Operating Profit
633
478
420
508
601
657
598
762
804
909
1,179
1,309
1,420
OPM %
19%
17%
14%
18%
19%
20%
20%
23%
25%
26%
31%
34%
34%
Other Income
149
125
119
70
102
79.01
9
1,401
101
123
149
145
203
Interest
0
0
0
0
1
6
4
2
2
2
1
3
3
Depreciation
25
25
27
38
49
83
79
68
66
70
67
66
64
Exceptional Items
—
—
—
—
28.69
−341
—
—
—
−144
—
20.62
—
PBT
756
578
511
540
683
306
525
2,093
836
816
1,260
1,406
1,555
Tax %
37%
35%
34%
35%
35%
70%
32%
19%
27%
28%
26%
26%
—
Net Profit
476
376
337
351
445
93
358
1,695
611
590
928
1,036
1,147
EPS (₹)
28.12
22.20
19.88
20.70
26.29
5.50
21.14
100.04
36.05
34.83
54.75
61.15
67.68
Div. Payout %
111%
113%
75%
85%
76%
727%
142%
90%
89%
92%
99%
93%
—
Sales growth
29
−14
2
−1
9
3
−9
12
−1
6
9
2
12

Balance Sheet

₹ Cr
GLAXO balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
85
85
85
85
169
169
169
169
169
169
169
169
169
Reserves
1,744
2,099
1,922
1,973
1,970
1,651
1,309
2,494
1,572
1,608
1,782
2,098
1,712
Borrowings
3
2
2
1
1
0
35
20
16
19
10
33
39
Other Liabilities
1,384
869
995
1,889
1,771
1,315
1,602
1,950
1,570
1,760
2,147
2,023
2,048
Total Liabilities
3,216
3,055
3,004
3,947
3,911
3,136
3,115
4,633
3,327
3,557
4,108
4,324
3,969
Fixed Assets
123
204
258
325
432
758
387
331
330
321
284
281
293
CWIP
115
268
605
923
1,003
120
13
30
20
14
14
33
35
Investments
0
6
0
0
0
0
0
366
518
813
1,118
1,392
1,525
Other Assets
2,977
2,577
2,140
2,700
2,477
2,257
2,715
3,907
2,458
2,408
2,692
2,618
2,116
Total Assets
3,216
3,055
3,004
3,947
3,911
3,136
3,115
4,633
3,327
3,557
4,108
4,324
3,969

Cash Flow

₹ Cr
GLAXO cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
338
139
234
473
409
490
578
811
484
582
1,290
903
Investing
180
499
301
−104
−153
−57
418
−406
808
9
−46
397
Financing
−497
−638
−511
−307
−358
−428
−696
−524
−1,543
−562
−769
−737
Net Cash Flow
21
0
24
62
−102
6
300
−119
−251
29
475
563
Free Cash Flow
175
−69
−24
639
166
336
536
2,371
451
573
1,273
870
CFO/EBITDA
93
72
94
133
101
103
121
122
93
92
116
93

Ratios

GLAXO financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
11
16
21
19
14
11
27
23
22
23
28
26
Inventory Days
91
156
111
147
131
135
159
144
131
144
126
124
Days Payable
74
97
73
149
109
100
135
156
122
171
186
154
Cash Conversion Cycle
27
75
60
17
36
46
50
11
31
−4
−31
−4
Working Capital Days
−48
26
7
−90
−72
−38
−39
−94
−57
−64
−99
−91
ROCE %
42%
29%
22%
26%
31%
33%
38%
37%
36%
51%
63%
61%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view GlaxoSmithKline Pharmaceuticals insights

66 extracted metrics across FY14–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 75.00%
  • Public 9.65%
  • DIIs 8.48%
  • FIIs 4.75%
  • Others 2.12%

No promoter shares pledged as of Sep 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about GlaxoSmithKline Pharmaceuticals

What does Glaxosmithkline Pharmaceuticals Ltd do?
GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.
Where is Glaxosmithkline Pharmaceuticals Ltd (GLAXO) listed?
Glaxosmithkline Pharmaceuticals Ltd trades as GLAXO on the NSE and under code 500660 on the BSE.
Which sector does Glaxosmithkline Pharmaceuticals Ltd belong to?
Glaxosmithkline Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals & Biotechnology industry.
What is the market capitalisation of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd has a market capitalisation of ₹46,207 Cr as of 20 Nov 2026, which places it in the Midcap band.
What is the PE ratio of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd trades at a PE ratio of 40.30 as of 20 Nov 2026, on earnings per share of ₹67.68, against a book value of ₹111.04 per share.
What is the 52-week high and low of Glaxosmithkline Pharmaceuticals Ltd?
Over the last 52 weeks Glaxosmithkline Pharmaceuticals Ltd has traded between ₹2,088.1 and ₹3,120.7 as of 20 Nov 2026.
Does Glaxosmithkline Pharmaceuticals Ltd pay dividends?
Glaxosmithkline Pharmaceuticals Ltd has a dividend yield of 2.10%.
What is the Return on Equity (ROE) of Glaxosmithkline Pharmaceuticals Ltd?
Glaxosmithkline Pharmaceuticals Ltd reported a return on equity of 45.60%. Its debt-to-equity ratio is 0.02.

Company Information

GlaxoSmithKline Pharmaceuticals research, manufacture and make available a broad range of medicines and vaccines that benefit people.

CEO Mr. Bhushan Akshikar
Employees 3,113
Listed 15 Dec 2000
Face Value ₹10
Shares Outstanding 16,94,06,034

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/GLAXO.md for Glaxosmithkline Pharmaceuticals Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More